Introduction
Calcium is involved in many biological processes including the many neural processes in the body [1] [2] . Altered neuronal calcium homeostasis is widely hypothesized to underlie cognitive deficits in normal aging subjects, and many neurodegenerative diseases including Alzheimer's disease (AD) [2] [3] [4] [5] [6] . A polymorphism rs2986017 in CALHM1
influences calcium ion homeostasis, beta amyloid levels, and AD risk 7 .
Until now, most studies focused on the association between calcium homeostasis and AD, and concerned the intracellular calcium concentration 2, [4] [5] [6] [7] . The involvement of intracellular calcium dysregulation in AD has been well established 2 . A recent article updated the calcium hypothesis of AD on the basis of emerging evidence since 1994 8 .
This updated hypothesis provided a framework for integrating new evidence such as aging, genetic, and environmental factors into a comprehensive theory of pathogenesis 8 .
To develop more effective therapies, we should establish the causal links between the clinical and neurobiological phenotypes of dementia and neurodegeneration 8 . Mendelian randomization method using large-scale genome-wide association study (GWAS) datasets could avoid some limitations of observational studies, and is widely used to determine the causal inferences 1, [9] [10] [11] . However, there is no GWAS to identify the causal variants influencing the calcium homeostasis or intracellular calcium levels. Until now, it is still impossible to detect the genetic relationships of calcium homeostasis or intracellular calcium levels with AD risk.
In addition to the calcium homeostasis and intracellular calcium levels in AD, evidence also highlighted the role of serum calcium levels in AD risk. Landfield et al. found that 6 AD cases were characterized by lower serum calcium levels compared with age-matched controls or demented subjects with mild indications of vascular contributions 12 . The serum chemistry tests further showed that moderately low values of phosphate, calcium, or both identified 74% of AD cases and 100% of early onset AD cases, compared with only 46% of mixed/vascular dementia cases and 31% of normal age-matched control samples 12 . Compared with mildly affected individuals, the severely demented patients had lower serum calcium levels 13 . Meanwhile, compared with normal age-matched controls, AD patients showed a decrease in serum calcium level, increase in serum parathyroid hormone level, increase in urinary calcium excretion, and a decrease in serum 1, 25 dihydroxyvitamin D (1,25(OH)2D) concentration 14 . However, it remains unclear whether serum calcium levels are genetically associated with AD risk.
In recent years, large-scale GWAS promptly identified some common genetic variants and provided insight into the genetics of serum calcium and AD [15] [16] . The existing large-scale GWAS datasets provide strong support for investigating the potential genetic association between serum calcium levels and AD risk by a Mendelian randomization analysis method. Here, we hypothesize that there may be a genetic relation between serum calcium levels and AD risk. We performed a Mendelian randomization study to investigate the potential genetic association using a large-scale serum calcium GWAS dataset and a large-scale AD GWAS dataset.
Materials and methods

Study Design
randomly distributed in the population 17 . These genetic variants are largely not associated with confounders and can be used as instrumental variables to estimate the causal association of an exposure (serum calcium levels) with an outcome (AD) 17 . The
Mendelian randomization is based on three principal assumptions (Figure 1 ), which have been widely described in recent studies 1, 17 . First, the genetic variants selected to be instrumental variables should be associated with the exposure (serum calcium levels) (assumption 1 in Figure 1 ) 1, 17 . Second, the genetic variants should not be associated with confounders (assumption 2 in Figure 1 ) 1, 17 . Third, genetic variants should affect the risk of the outcome (AD) only through the exposure (serum calcium levels) (assumption 3 in Figure 1 ) 1, 17 . The second and third assumptions are collectively known as independence from pleiotropy 17 . This study is based on the publicly available, large-scale GWAS summary datasets. All participants gave informed consent in all these corresponding original studies.
Figure 1 Serum Calcium GWAS Dataset
Here, we selected genetic variants that influence serum calcium levels as the instrumental variables based on the GWAS dataset of serum calcium concentration 15 . This GWAS included 39400 individuals from 17 population-based cohorts in discovery stage and 21679 individuals in replication stage (N=61079 individuals of European descent) 15 . The 8 discovery stage and the meta-analysis of the discovery and replication stage identified 8 genetic variants to be associated with serum calcium levels with the genome-wide significance (P < 5.00E-08) 15 . All these 8 genetic variants were located in different genes and were not in linkage disequilibrium (Table 1) 15 . We provided more detailed information about the methods to measure serum calcium levels in the eTable 1.
AD GWAS Dataset
The AD GWAS dataset is from the large-scale meta-analysis, which is performed by the International Genomics of Alzheimer's Project (IGAP) 16 . In stage 1, the IGAP genotyped and imputed 7,055,881 SNPs, and performed a meta-analysis of four GWAS datasets including 17,008 cases and 37,154 controls of European descent 16 . All patients with AD satisfied the NINCDS-ADRDA criteria or DSM-IV guidelines 16 . Here, we extracted the summary statistics of these 8 genetic variants with AD risk in stage 1 dataset.
Pleiotropy Analysis
In Mendelian randomization study, one important issue is potential violation of assumption 2 and 3 through pleiotropy occurring when a genetic instrument is associated with a study outcome through biological pathways outside the exposure of interest. Here, we performed an assessment for pleiotropy to assure that the selected genetic variants do not exert effects on AD risk through biological pathways independent of serum calcium levels. A number of steps were taken to reduce the risk of pleiotropy. Here, we provided more detailed information about five stages of pleiotropy analysis in eMethods.
Mendelian Randomization Analysis
Until now, three different Mendelian randomization analysis methods have been well established including inverse-variance weighted meta-analysis (IVW), weighted median regression and MR-Egger regression 1, [9] [10] [11] [17] [18] [19] [20] . Here, we selected the IVW as the main analysis method to perform the Mendelian randomization analysis, as did in previous studies 1, [9] [10] [11] [17] [18] [19] [20] . Meanwhile, we selected the weighted median regression and MR-Egger regression as the complementary analysis methods to examine the robustness of the IVW estimate. The weighted median regression method could derive consistent estimates when up to 50% of instruments are not valid 17 . MR-Egger could provide a statistical test the presence of potential pleiotropy, and account for this potential pleiotropy [19] [20] . If there is no clear evidence of pleiotropy, we would expect all three tests to give consistent estimates. The odds ratio (OR) as well as 95% confidence interval (CI) of AD corresponds to per 0.5-mg/dL increase (about 1 standard deviation (SD)) in serum calcium levels. All analyses were conducted using the R package 'MendelianRandomization' 21 . The threshold of statistical significance for the potential genetic association between serum calcium levels and AD risk was P < 0.05. We also performed a sensitivity analysis using the leave-one-out permutation method, and a power analysis. Here, we provided more detailed information about the IVW, weighted median, MR-Egger regression, sensitivity analysis and power analysis in the eMethods.
Results
Genetic variant validation
In addition to statistical association, all these 8 genetic variants could map to genes implicated in calcium pathways or related phenotypic traits 15 . In brief, GCKR, DGKD, CASR, GATA3, DGKH/KIAA0564, CYP24A1, and CARS were associated with bone metabolism and endocrine control of calcium 15 . More detailed information has been described in previous study 15 . The physiological function of VKORC1L1, a paralogous enzyme sharing about 50% protein identity with VKORC1, is unknown. However previous findings showed that VKORC1 could inhibit calcium oxalate salt crystallization, adhesion and aggregation 22 .
Association of serum calcium variants with AD
Of these 8 genetic variants associated with serum calcium levels, we successfully extracted the summary statistics for 7 variants in stage 1 dataset of AD GWAS. The rs17711722 is not available in stage 1 dataset of AD GWAS. We then selected its proxy rs1829942, which showed high LD with rs17711722 (r²=0.91 and D'=0.96) using the HaploReg v4.1 based on LD information in 1000 Genomes Project (CEU) with r 2 >= 0.8 23 . None of these 8 genetic variants was significantly associated with AD risk at the Bonferroni corrected significance threshold (P<0.05/8=0.0063) ( Table 1) . Table 2) .
Table 2
In summary, our pleiotropy analysis showed that rs780094 and rs7481584 may have potential violation of assumption 2 and 3 through pleiotropy. To meet the Mendelian randomization assumptions (Figure 1 ), we excluded both variants in following analysis.
Association of serum calcium with AD risk
Using the remaining 6 genetic variants, IVW analysis showed that a genetically increased serum calcium level (per 1 SD increase 0.5-mg/dL) was significantly associated with a reduced AD risk (OR=0.56, 95% CI: 0.34-0.94, P=5.00E-03) ( between these 6 variants. Figure 2 shows individual genetic estimates from each of the 6 genetic variants using different methods.
Figure 2
To further test the stability of these estimates, we sequentially removed each genetic variant in the Mendelian randomization analysis. The direction and precision of the genetic estimates between increased serum calcium levels and reduced risk of AD remained largely unchanged using all these three Mendelian randomization methods (Table 3) . Table 3 Power analysis
We further performed a power analysis using the strength of the instrumental variables (6 genetic variants) R 2 0.81%, the actual N for AD GWAS 54,162, and the proportion of cases 0.314. Interestingly, the power is 100% to detect the genetic association between increased serum calcium levels and reduced AD risk with OR=0.56. The N required for 80% power is 16427.
Discussion
Until now, it has been a long time about the calcium hypothesis of AD on the basis of emerging evidence since 1994 8 . However, most studies focused on the association between calcium homeostasis and AD, and concerned the intracellular calcium concentration 2, [4] [5] [6] [7] . Only few studies reported reduced serum calcium levels in AD [12] [13] [14] .
Until now, it remains unclear whether serum calcium level (diet and supplements) is genetically associated with AD risk. Fortunately, the existing large-scale serum calcium and AD GWAS datasets prompts us to investigate the potential genetic association between serum calcium and AD risk by a Mendelian randomization method. Our findings indicated genetically increased serum calcium levels were significantly associated with a reduced AD risk. Each SD higher serum calcium level (1SD=0.5 mg/dL) was associated with a 44% reduced AD risk (OR=0.56, 95% CI: 0.34-0.94, P=5.00E-03).
Interestingly, our results are consistent with previous studies, which reported reduced serum calcium levels in AD [12] [13] [14] . Meanwhile, a recent study also reported the reduced serum calcium levels in Parkinson's disease 27 . The levels of serum calcium in
Parkinson's disease group with dementia were significantly lower than the normal control group (P<0.001) 27 . There is also a correlation between serum calcium levels and cognitive impairment 27 . Lower serum calcium levels could predict worse cognitive scores 27 .
More than 99% of calcium in human body is stored in the skeleton as hydroxyapatite contributing to skeletal strength 28 . Only less than 1% of calcium is located in the blood, soft tissues, and extracellular fluid 28 . . It is difficult to get this recommended amount through diet alone, so calcium supplements are widely used 31 . In the United States, about 43% of people, including about 70% of older women, take calcium supplements 32 . Hence, the genetic association between serum calcium levels and AD risk may have clinical and public health implications.
Until now, our findings should be considered to be exploratory, as did in observational studies. In order to translate these genetic findings into clinical and public health implications, the potential mechanisms underlying this genetic association remain to be thoroughly evaluated. Meanwhile, randomized controlled study should be conducted to assess the effect of serum calcium levels on AD risk, and further clarify whether diet calcium intake or calcium supplement, or both could reduce the risk of AD.
Strengths
This Mendelian randomization study has several strengths. First, this study may benefit from the large-scale serum calcium GWAS dataset (N=61079 individuals) and AD GWAS dataset (N=54,162 individuals), which provide ample power (100%) to detect the genetic association between serum calcium levels and AD risk. Second, both the serum calcium and AD GWAS datasets are from the European descent, which may reduce the influence on the potential association caused by the population stratification. Third, multiple independent genetic variants are taken as instruments, which may reduce the influence on the potential association caused by the linkage disequilibrium. Fourth, we selected multiple Mendelian randomization methods, which increase the precision of the estimate. Fifth, we performed a pleiotropy analysis to exclude two genetic variants associated with potential confounders, which meets the Mendelian randomization assumptions.
Limitations
First, we only selected one AD GWAS dataset. We think that a replication data may be necessary. However a replication dataset with a similar large-scale of AD GWAS dataset was not available. Second, five steps were taken to reduce the risk of pleiotropy, as did in our pleiotropy analysis. However, we could not completely rule out additional confounders. Until now, it is almost impossible to fully rule out pleiotropy present in any
Mendelian randomization study 1, 17, 33 . Third, it could not be completely ruled out that population stratification may have had some influence on the estimate. In order to reduce the effect of population stratification, our study was restricted to individuals of European ancestry. Fourth, the genetic association between serum calcium levels and AD risk may differ by ethnicity or genetic ancestry. This genetic association should be further evaluated in other ancestries.
Fifth, Mendelian randomization can be extended to conduct a mediation analysis, estimating the proportion of an observed association of an exposure with an outcome that occurs through a given mediator 17 . Until now, there is no GWAS to evaluate the calcium channel blockers. Hence, we could not conduct the medication analysis, as the medication data is not available now. In our further work, we will further conduct the medication analysis, when the medication data is publicly available.
Sixth, polygenic risk score (PRS) is another measure of genetic predisposition 17 . PRS is conceptually similar to Mendelian randomization 34 . There are also some differences 34 .
Mendelian randomization study just uses two summary GWAS datasets. The PRS method uses one summary GWAS dataset, and one genotype data. Until now, a large-scale AD GWAS dataset with the individual genotype data is not publicly available. In our further work, we will further conduct a PRS analysis, when the individual genotype data is publicly available.
Conclusions
In summary, we demonstrate that genetically increased serum calcium levels could reduce AD risk in people of European descent using large-scale GWAS datasets. These findings provide rationale for further investigating the clinical and public health implications of high serum calcium levels by diet or supplement, or both in preventing the progression of AD. 15 . c Summary statistics (beta coefficient, standard error and P value) were obtained from a serum calcium GWAS dataset including up to 61079 individuals of European ancestry 15 . Beta (mg/dL) is the regression coefficient based on the serum calcium raising allele (effect allele). Beta > 0 and Beta < 0 means that this effect allele regulates increased and reduced serum calcium levels, respectively. d Summary statistics (beta coefficient, standard error and P value) were obtained from International Genomics of Alzheimer's Project including 17,008 cases and 37,154 controls of European descent 16 . Beta is the regression coefficient based on the serum calcium raising allele (effect allele). Beta > 0 and Beta < 0 means that this effect allele regulates increased and reduced AD risk, respectively. Beta is the overall estimated effect size for the effect allele, beta=ln(odd ratio); * rs17711722 is not available in AD GWAS dataset. We selected rs1829942, which showed high LD with rs17711722 (r²=0.91 and D'=0.96) using the HaploReg v4.1 based on LD information in 1000 Genomes Project (CEU) 23 . Table 1 ). b represents the summary effect estimate by including all these 6 genetic variants in the Mendelian randomization analysis (presented in Table 1 ).
Figure 1. Mendelian randomization assumptions
The Mendelian randomization is based on three principal assumptions, which have been widely described in recent studies 1, 17 . First, the genetic variants selected to be instrumental variables should be associated with the exposure (serum calcium levels) (assumption 1) 1, 17 . Second, the genetic variants should not be associated with confounders (assumption 2) 1, 17 . Third, genetic variants should affect the risk of the outcome (AD) only through the exposure (serum calcium levels) (assumption 3) 1, 17 . 
